Previous 10 | Next 10 |
-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse -Company to Host Quarterly Conference Call at 8:30 am ET Today CORAL GABLES, Fla., May 13,...
This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...
Gainers: Bridgeline Digital (NASDAQ: BLIN ) +30% . Cohu (NASDAQ: COHU ) +27% . ATA (NASDAQ: ATAI ) +25% . ARCA biopharma (NASDAQ: ABIO ) +24% . SolarEdge Technologies (NASDAQ: SEDG ) +23% . Summit Wireless Technologies (NASDAQ: WISA ) +22% . Itron (NASDAQ: ITRI ) +21% . Sunwor...
Catalyst Pharmaceuticals ( CPRX ) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first app...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) -39% after FDA OKs Firdapse competitor. More news on: Catalyst Pharmaceuticals, Inc., Intersect ENT, Inc., TherapeuticsMD, Inc., Stocks on the move, Read more ...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) -42.7% after-hours following the Food and Drug Administration's approval of a competitor to its Firdapse drug that helps patients who suffer from Lambert-Eaton myasthenic syndrome, for which CPRX charges a list price of $375K. More news on: Cata...
CORAL GABLES, Fla., May 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today...
Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...
March 26, 2019 Palm Beach, FL – March 26, 2019 – Research for the cure for cancer has become this generation’s version of President John F. Kennedy’s May 25, 1961 proclamation to “… landing a man on the Moon and returning him safely”. ...
(Rendition of Brain Neurons, Source: NIH) The biotech sector has continued to participate in the market rally. One of the reasons is the strength in biopharma M&A activity, which provides unique support for valuations and particularly assists the small-and-midcap biotech companies. We ...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...